- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06803771
Vigilância da saúde pancreática após diagnóstico de diabetes (SAFE-D)
An Interventional Study to Evaluate the cfDNA Pancreatic Cancer Test (Avantect) in the Early Detection of Pancreatic Cancer in Participants With Newly Diagnosed Diabetes Mellitus or Newly Elevated HbA1c
The goal of this interventional study is to evaluate if the novel diagnostic blood test, called Avantect can early detect pancreatic cancer in patients diagnosed with type 2 diabetes or with elevated sugar levels within the last 200 days.
Participants will:
- attend 3 study visits over 12 months time
- provide a blood sample at each study visit
- complete an anxiety questionnaire at each visit.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Pancreatic cancer (PC) is one of the most lethal common cancers (five-year survival 5-7%). In more than 80% of patients the disease has spread before it is detected, ruling out potentially curative treatment options. Early detection offers the possibility of surgery leading to significantly improved overall survival.
There is currently no accepted screening test for pancreatic cancer. The Aventect test is designed to detect clues, or biomarkers for the presence or absence of pancreatic cancer signals in blood. The SAFE-D study will evaluate if the Avantect test can detect pancreatic cancer at an earlier more treatable stage.
People older than 50 years who have recently been diagnosed with type II diabetes have up to ten times higher-than-average risk of having pancreatic cancer without knowing.
The study will recruit 5,000 participants aged 50-84 years old diagnosed with type II diabetes or elevated Hb1Ac levels within the last 200 days from GP practices over 3 years.
Participants will have their blood samples analysed on the Avantect test as soon as possible. If a pancreatic biomarker is detected the participants will be informed and offered a standard of care diagnostic imaging scan (MRI or CT) to rule out pancreatic cancer. All participants will be followed remotely via cancer and mortality registry searches for 3 years from consent to assess any cancer diagnosed during this time.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Não aplicável
Contactos e Locais
Contato de estudo
- Nome: SAFE-D Trial Manager
- Número de telefone: +442381205154
- E-mail: safed@soton.ac.uk
Locais de estudo
-
-
-
Ashton-under-Lyne, Reino Unido, OL6 6HD
- Ativo, não recrutando
- Ashton Medical Group
-
Birmingham, Reino Unido, B14 4DU
- Recrutamento
- Yardley Wood Health Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Bournemouth, Reino Unido, BH7 7DW
- Ativo, não recrutando
- Bournemouth Research Hub
-
Bromborough, Reino Unido, CH62 6EE
- Recrutamento
- Eastham Group Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Reino Unido, NW10 2PT
- Recrutamento
- Willesden Medical Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Reino Unido, SW1P 2PF
- Recrutamento
- South Westminster Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
London, Reino Unido, W7 1DR
- Recrutamento
- The Cuckoo Lane Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Manchester, Reino Unido, M14 6WP
- Ativo, não recrutando
- Bodey Medical Centre
-
Manchester, Reino Unido, M23 1JX
- Ativo, não recrutando
- Bowland Medical Practice
-
Manchester, Reino Unido, M23 2SY
- Ativo, não recrutando
- The Maples Medical Centre
-
Nottingham, Reino Unido, NG17 4JL
- Recrutamento
- King's Mill Hospital (Sherwood Forest) Research Van
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Portsmouth, Reino Unido, PO1 3HN
- Ativo, não recrutando
- Portsmouth Research Hub
-
Rossendale, Reino Unido, BB4 5SL
- Recrutamento
- Hazelvalley Family Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Ruislip, Reino Unido, HA4 8NX
- Recrutamento
- Pembroke Centre (Hillingdon)
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Reino Unido, SO30 3JB
- Recrutamento
- Moorgreen Hospital
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Southampton, Reino Unido, SO15 33UA
- Ativo, não recrutando
- Southampton Research Hub (Shirley Research Hub)
-
Uttoxeter, Reino Unido, ST14 8JG
- Recrutamento
- Balance Street Health Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Uxbridge, Reino Unido, UB8 1UW
- Recrutamento
- Civic Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Walsall, Reino Unido, WS6 6EW
- Recrutamento
- Quinton Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Weymouth, Reino Unido, DT4 0QE
- Ativo, não recrutando
- Weymouth Research Hub
-
-
Cheshire
-
Sandbach, Cheshire, Reino Unido, CW11 1EQ
- Ativo, não recrutando
- Ashfields Primary Care Centre
-
-
Kent
-
Maidstone, Kent, Reino Unido, ME16 9QQ
- Recrutamento
- Maidstone and Tunbridge Wells NHS Trust
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicester Forest East
-
Leicester, Leicester Forest East, Reino Unido, LE3 3LW
- Recrutamento
- Forest Medical Group
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Leicestershire
-
Kibworth Beauchamp, Leicestershire, Reino Unido, LE8 0LG
- Recrutamento
- South Leicestershire Medical Group
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Staffordshire
-
Burton-on-Trent, Staffordshire, Reino Unido, DE14 3RH
- Recrutamento
- Peel Croft Surgery
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Kingswinford, Staffordshire, Reino Unido, DY6 8DN
- Recrutamento
- Kingswinford Medical Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Leek, Staffordshire, Reino Unido, ST13 6QR
- Recrutamento
- Park Medical Centre
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Stratford-upon-Avon, Staffordshire, Reino Unido, CV37 6HJ
- Recrutamento
- Trinity Court Surgery
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Surrey
-
Brockham, Surrey, Reino Unido, RH3 7NJ
- Recrutamento
- Brockwood Medical Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Epsom, Surrey, Reino Unido, KT17 4BL
- Recrutamento
- Integrated Care Partnership/ The Old Cottage Hospital
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
Warlingham, Surrey, Reino Unido, CR6 9NW
- Recrutamento
- Warlingham Green Medical Practice
-
Contato:
- Anson-Wisniewska
- Número de telefone: 02380215154
- E-mail: safed@soton.ac.uk
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- 50 - 84 years of age at the time of enrolment (within year of birth, not month of birth)
- Confirmed type 2 DM diagnosis established within the last 200 days or an initial elevated HbA1c ≥ 48 mmol/mol or 6.5% obtained within the last 200 days. This includes people who have a first elevated HbA1c (≥ 48 mmol/mol or 6.5%) within the last 200 days, even if subsequent HbAc1 measurements return to the the normal range.
- Willing to provide up to 30 mL of blood for each study visit
- Willing and eligible to undergo MRI or CT scan
- Understands the study process and is willing to take part in the study and sign the informed consent form
Exclusion Criteria:
- Prior type I or type II DM diagnosis or an initial HbA1c ≥ 48 mmol/mol or 6.5% obtained prior to the 200-day inclusion window, except gestational elevated HbA1c.
- A history of pancreatic cancer, pancreatic neuroendocrine tumour (pNET) or Pancreatitis
- Under investigation for or confirmed pancreatic cancer
- Under investigation/surveillance for pancreatic cyst
- Any known pancreatic surgery (not including ERCP), or other major surgery requiring anaesthesia within 3 months
- Any invasive solid or haematological cancer in the past 3 years, including cancer recurrence after treatment in the last 3 years
- BMI > 40 at the time of consent
- Blood transfusion within 1 month
- Solid organ transplant recipient
- Currently pregnant
- Needing dialysis
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Diagnóstico
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Interventional
Participants will have their blood samples tested on the Avantect test within prioritised timeframe. The "detected" Avantect test results will be shared with the participants and their General Practitioners (GPs) to allow for further MRI or CT investigations by the local clinical team. |
Avantect test |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Sensitivity of the Avantect test
Prazo: The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "detected" test result who have pancreatic cancer diagnosed via imaging in relation to all individuals in the study who had pancreatic cancer diagnosed. |
The final analysis will be carried out after 3-year follow up data has been collected for all 5,000 participants.
|
|
Specificity of the Avantect test
Prazo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of individuals with one or more Avantect "not detected" test results, and no Avantect "detected" results, who did not have a pancreatic cancer diagnosis in relation to all individuals in the study who did not have a pancreatic cancer diagnosis. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Stage shift
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
The proportion of pancreatic cancers cases diagnosed at stage I/II out of all participants diagnosed with pancreatic cancer between SAFE-D participants and point-estimate of the proportion from comparative data. Stage shift will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Positive Predictive Value (PPV) of Avantect test in detecting pancreatic cancer (PC)
Prazo: The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with an Avantect "detected" result who have pancreatic cancer diagnosed. The analysis will be conducted with a sample size of 5,000, pancreatic cancer prevalence of 0.8%, and 5% lost from the per protocol population. There will be an expected 261 individuals with an Avantect "detected" result. 9.6% (25/261) are expected to have a PC. PPV will be considered successful if a null PPV of 5% can be ruled out at a one-sided p-value of 0.05. |
The final analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Negative Predictive Value (NPV) of Avantect test in ruling out pancreatic cancer (PC)
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
With a sample size of 5,000, PC prevalence of 0.8%, and 5% lost from the per protocol population, there will be an expected 4,489 individuals without an Avantect "detected" result. 99.6% (4,476/4,489) are expected to not have a diagnosis of PC. NPV will be considered successful if a null NPV of 99% can be ruled out at a one-sided p-value of 0.05. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resection rate of pancreatic cancer
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of participants with pancreatic cancer who underwent resection. The analysis will be conducted by comparing the proportion of pancreati cancer cases that underwent resection as a treatment modality between SAFE-D participants and the point-estimate of the proportion from comparative data. Resection rate will be considered successful if the lower-bound of the 95% one-sided proportion in SAFE-D participants is higher than the proportion from comparative data. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Resectability
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Percentage of pancreatic cancers deemed resectable by the study MDST. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time-to-event outcomes
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the time from new onset diabetes diagnosis to pancreatic cancer diagnosis. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Overall survival
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To estimate the overall survival of study participants. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
Effect of the Avantect test on state anxiety over time
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To assess the effect of the Avantect test on state anxiety over time. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
|
High-grade neoplasia
Prazo: The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
To investigate the performance characteristics for high-grade neoplasia. |
The analysis will be carried out after 3-year follow-up data has been collected for all 5,000 participants.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicações e links úteis
Links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do Sistema Endócrino
- Neoplasias por local
- Neoplasias
- Doenças Metabólicas
- Neoplasias do Aparelho Digestivo
- Doenças do aparelho digestivo
- Distúrbios do Metabolismo da Glicose
- Neoplasias das Glândulas Endócrinas
- Doenças pancreáticas
- Doenças Nutricionais e Metabólicas
- Diabetes Mellitus, Tipo 2
- Neoplasias Pancreáticas
- Diabetes Mellitus
- Câncer de pâncreas, adulto
Outros números de identificação do estudo
- RHMGSU0292
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .